A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis

Cancer

Volumn 119, Issue 18, 2013, Pages 3354-3358

  Yamaguchi, Hironori ^a   Kitayama, Joji ^a   Ishigami, Hironori ^a   Emoto, Shigenobu ^a   Yamashita, Hiroharu ^a   Watanabe, Toshiaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

gastric cancer; intraperitoneal chemotherapy; paclitaxel; peritoneal metastasis; phase 2 study; S 1

Indexed keywords

GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; GASTRECTOMY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MALE; MALIGNANT ASCITES; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

GASTRIC CANCER; INTRAPERITONEAL CHEMOTHERAPY; PACLITAXEL; PERITONEAL METASTASIS; PHASE 2 STUDY; S-1;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; OXONIC ACID; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR;

EID: 84883598473     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28204     Document Type: Article

References (19)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 2893-2917.
2. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345: 725-730.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24: 4991-4997. (Pubitemid 46631401)
4. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9: 215-221.
5. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000; 88: 358-363. (Pubitemid 30051820)
6. Yamada Y, Shirao K, Ohtsu A, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001; 12: 1133-1137. (Pubitemid 32834495)
7. Yamaguchi K, Tada M, Horikoshi N, et al. Paclitaxel Gastric Cancer Study Group in Japan. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer. 2002; 5: 90-95. (Pubitemid 34832243)
8. Armstrong DK, Bundy B, Wenzel L, et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354: 34-43. (Pubitemid 43048949)
9. Ishigami H, Kitayama J, Otani K, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009; 76: 311-314.
10. Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010; 21: 67-70.
11. Harmon RL, Sugarbaker PH,. Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int. Semin. Surg. Oncol. 2005; 2: 3.
12. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma-2nd English Edition. Gastric Cancer. 1998; 1: 10-24.
13. Gelderblom H, Verweij J, van Zomeren DM, et al. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res. 2002; 8: 1237-1241. (Pubitemid 35177380)
14. Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG,. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 1989; 49: 3380-3384. (Pubitemid 19162154)
15. Soma D, Kitayama J, Konno T, et al. Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer. Cancer Sci. 2009; 100: 1979-1985.
16. Kamei T, Kitayama J, Yamaguchi H, et al. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. Cancer Sci. 2011; 102: 200-205.
17. Sugarbaker PH, Stuart OA, Vidal-Jove J, Pessagno AM, DeBruijn EA,. Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration. Cancer Treat Res. 1996; 82: 41-52.
18. Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol. 2009; 100: 311-316.
19. Fujiwara Y, Takiguchi S, Nakajima K, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012; 105: 38-42.